Nabumetone: a clinical appraisal.
Nonsteroidal antiinflammatory drugs (NSAIDs) have long been used as therapy for arthritis patients. However, in some patients these drugs can cause gastrointestinal hemorrhage, perforation, or ulcer through direct topical effects, enterohepatic recirculation, and systemic effects. In an effort to address this problem, new NSAIDs have been developed. Nabumetone, which belongs to a new class of NSAID, is a nonacidic agent that has been associated with a low incidence of peptic ulcer. This article examines available clinical data on nabumetone, including studies on gastrointestinal safety and effectiveness in osteoarthritis and rheumatoid arthritis patients, and data that may provide an explanation for nabumetone's low incidence of ulceration.
Helfgott
S M
SM
Department of Rheumatology and Immunology, Brigham and Women's Hospital, Boston, MA 02115.
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects / Q000592:standards / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D002074:Butanones / Q000009:adverse effects / Q000592:standards / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D006801:Humans; D000077430:Nabumetone; D010003:Osteoarthritis / Q000188:drug therapy*
D000894:Anti-Inflammatory Agents, Non-Steroidal; D002074:Butanones; D000077430:Nabumetone